Comparative Pharmacology
Head-to-head clinical analysis: NABUMETONE versus NAPRELAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NABUMETONE versus NAPRELAN.
NABUMETONE vs NAPRELAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that acts as a non-selective inhibitor of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Its active metabolite, 6-methoxy-2-naphthylacetic acid (6MNA), is responsible for its therapeutic effects.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, which mediates pain, inflammation, and fever.
1000 mg orally once daily with food; may increase to 1500-2000 mg/day in divided doses if needed.
750 mg to 1000 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 22-30 hours in healthy adults, allowing once-daily dosing. Steady state is achieved after 3-5 days.
Clinical Note
moderateNabumetone + Gatifloxacin
"Nabumetone may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateNabumetone + Rosoxacin
"Nabumetone may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateNabumetone + Levofloxacin
"Nabumetone may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateNabumetone + Trovafloxacin
"Nabumetone may increase the neuroexcitatory activities of Trovafloxacin."
Terminal elimination half-life: 10-20 hours; context: allows twice-daily or once-daily dosing for chronic pain or inflammation.
Approximately 80% of a dose is excreted in urine as metabolites (primarily 6-methoxy-2-naphthylacetic acid and its glucuronide conjugates), with about 10% excreted in feces. Biliary excretion is minimal.
Renal: 50-60% as metabolites and conjugates; biliary/fecal: ~5%; remainder uncharacterized.
Category D/X
Category C
NSAID
NSAID